2026-01-04 - Analysis Report
Here's a comprehensive analysis of Natera Inc. (NTRA) based on the provided data:

**1) Return Comparison:**

*   **Company Overview:** Natera Inc. is a genetic testing company focused on non-invasive prenatal testing and cancer screening.
*   **NTRA Cumulative Return:** 126.28%
*   **VOO (S&P 500) Cumulative Return:** 91.00%
*   **Divergence:** 36.28
*   **Relative Divergence:** 47.9

**Analysis:** NTRA has significantly outperformed the S&P 500 (VOO) in cumulative return. However, the relative divergence of 47.9 suggests that while currently positive, the outperformance is somewhat moderate when considering the historical range of divergence between NTRA and VOO.

**Alpha/Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
|------------|--------|--------|---------|--------|--------|
| 2016-2018  | 16.0%  | 56.0%  | 13.0%   | 1.5    | 1.9    |
| 2017-2019  | 49.0%  | 58.5%  | 32.0%   | 1.7    | 4.7    |
| 2018-2020  | 177.0% | 58.5%  | 156.0%  | 1.3    | 13.9   |
| 2019-2021  | 89.0%  | 33.9%  | 46.0%   | 1.4    | 13.0   |
| 2020-2022  | -74.0% | 76.8%  | -72.0%  | 1.4    | 5.6    |
| 2021-2023  | -183.0%| 76.8%  | -184.0% | 1.6    | 8.7    |
| 2022-2024  | 11.0%  | 60.6%  | -9.0%   | 1.5    | 22.1   |
| 2023-2025  | 158.0% | 39.0%  | 95.0%   | 1.3    | 31.9   |

**Analysis:**

*   **CAGR:** NTRA's CAGR varies significantly, showing periods of high growth (e.g., 2018-2020, 2023-2025) and substantial declines (e.g., 2020-2022, 2021-2023).
*   **MDD:** Maximum Drawdown (MDD) indicates substantial risk, with drawdowns often exceeding 50%. This highlights the stock's volatility.
*   **Alpha:** Alpha reflects the stock's performance relative to its expected return based on its beta. High positive alpha indicates outperformance. However, negative alpha in some periods (2020-2022, 2021-2023, 2022-2024) indicates underperformance compared to what would be predicted based on its beta.
*   **Beta:** Beta consistently ranges between 1.3 and 1.7, suggesting NTRA is more volatile than the market.
*   **Cap(B):** Market Cap has grown quite a bit, indicating overall health of the firm.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 228.84
*   **Previous Close:** 229.09
*   **Change:** -0.11
*   **5-day SMA:** 230.59
*   **20-day SMA:** 232.74
*   **60-day SMA:** 212.51

**Analysis:** The stock price is slightly down from the previous close. The 5-day and 20-day SMAs are above the current price, indicating a possible short-term downtrend. The 60-day SMA is well below the current price, which suggests that the stock has been trending upwards over the past few months.

**3) Technical Indicators and Expected Return:**

*   **MRI:** 0.8 (Medium Investment Recommended)
*   **RSI:** 45.74 (Neutral)
*   **PPO:** -0.73 (Slightly Oversold)
*   **Hybrid Signal:** Cash_0%_Buy 100% of cash (4 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -1.8 (Short-term decline)
*   **Expected Return (%):** -44.5 (Compared to S&P 500 over 2 years)

**Analysis:** The MRI suggests a medium level of investment attractiveness. The RSI is neutral, indicating neither overbought nor oversold conditions. The negative PPO suggests the stock is slightly oversold. The negative Expected Return raises a concern, suggesting potential underperformance compared to the S&P 500 over the next two years if the current trend continues. The recent decline in relative divergence and minor change in the most recent price also suggests a near term pull back.

**4) Recent News & Significant Events:**

*   **Positive:**
    *   **[2026-01-03] Natera (NASDAQ:NTRA) Upgraded at Zacks Research:**  Analyst upgrades are generally positive signals.
    *   **[2025-12-11] Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks:**  Investment from a prominent investor can boost confidence.
    *   **[2025-12-15] Barclays Raises Natera (NTRA) Price Target to $270:**  Price target increases by analysts are positive.
    *   **[2025-12-30] Medical Stock Hovers Near Buy Point After 46% Gain:** Indicates recent positive momentum.
*   **Neutral/Cautionary:**
    *   **[2025-12-20] Natera (NTRA): Assessing Valuation After a Multi‑Year Share Price Surge:** A valuation assessment after a surge suggests investors should consider if the price is justified.
    *   **[2026-01-02] Responsive Playbooks and the NTRA Inflection:** Suggests a turning point or potentially significant shift in the stock's trajectory.

**Analysis:** The news is mixed. Analyst upgrades and institutional investment are positive. However, a valuation assessment after a price surge and talk of an "inflection" warrant caution and further investigation.

**4-2) Analyst Opinions:**

*   **Consensus:** Strong Buy (Mean: 1.47)
*   **Opinions:** 19
*   **Target Price (avg/high/low):** 248.37 / 285.00 / 186.00

**Analysis:**  The analyst consensus is strongly positive, with a "Strong Buy" rating and a significant number of opinions.  The average target price suggests potential upside from the current price. However, there is a wide range between the high and low target prices, which indicates some uncertainty among analysts. No recent rating changes are included in the information that can be reviewed.

**5) Recent Earnings Analysis:**

| 날짜        | EPS   | 매출      |
|-------------|-------|-----------|
| 2025-11-07  | -0.64 | 0.59 B$   |
| 2025-08-08  | -0.74 | 0.55 B$   |
| 2025-05-09  | -0.50 | 0.50 B$   |
| 2024-11-12  | -0.26 | 0.44 B$   |
| 2025-11-07  | -0.26 | 0.44 B$   |

**Analysis:** Natera has consistently reported negative EPS (Earnings Per Share). However, the most recent EPS is improving, and revenue is generally trending upwards.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|----------------|
| 2025-09-30   | $0.59B    | 64.91%         |
| 2025-06-30   | $0.55B    | 63.41%         |
| 2025-03-31   | $0.50B    | 63.12%         |
| 2024-12-31   | $0.48B    | 62.94%         |
| 2024-09-30   | $0.44B    | 61.79%         |

**Analysis:** Revenue is increasing steadily. The profit margin is quite high and also increasing, indicating improved efficiency.

**Capital and Profitability:**

| Quarter      | Equity    | ROE    |
|--------------|-----------|--------|
| 2025-09-30   | $1.25B    | -6.99% |
| 2025-06-30   | $1.25B    | -8.10% |
| 2025-03-31   | $1.24B    | -5.40% |
| 2024-12-31   | $1.20B    | -4.50% |
| 2024-09-30   | $0.88B    | -3.60% |

**Analysis:** Equity is growing, which is a positive sign. However, the Return on Equity (ROE) is negative, indicating that the company is not generating profits from its equity. Although ROE is still negative, it has been improving.

**7) Comprehensive Analysis (Summary):**

Natera (NTRA) presents a mixed picture:

*   **Strengths:** Strong historical outperformance vs. the S&P 500, high revenue growth and profit margins, a large and growing market cap, positive analyst ratings and price targets, recent analyst upgrades, recent investment from a prominent investor.
*   **Weaknesses:** High volatility (high Beta and MDD), consistently negative EPS, negative ROE (although improving), negative expected return compared to the S&P 500, recent negative divergence change, a valuation assessment after a multi-year surge, an inflection point could indicate uncertainty.

**Conclusion:**

NTRA is a high-growth, high-risk stock. While it has outperformed the market in the past and enjoys positive analyst sentiment, its financial performance (negative EPS and ROE) and high volatility should give investors pause. The news headlines suggest potential catalysts for further growth, but also potential risks related to valuation and future performance. It is a stock that requires careful monitoring and a high tolerance for risk. The negative expected return suggests that investors should consider the potential for underperformance compared to the S&P 500 before investing.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.